



Theragen™ Appoints Industry Veteran as Vice President of Sales to Drive Company's Expansion of ActaStim® Bone Growth Stimulator System

Jim Butler Brings Proven Track Record of High-Level Growth in Orthopedic and Spine Sectors

JACKSONVILLE, Fla., June 5, 2024 - Theragen Inc., a medical technology company and maker of the ActaStim® Bone Growth Stimulator System, has appointed orthopedic and spine industry veteran Jim Butler to its executive team as Vice President of Sales where he will play a key role in accelerating the company's growth.

Jim will lead the expansion of the sales channel across the country with the addition of strategic direct hires and new independent distribution partners as the company continues its growth in the orthopedic and spine sectors.

"Jim joins Theragen at an important moment in our company's journey as we continue to help patients get back on their feet in one of the most critical parts of the recovery journey following spine fusion surgery," said Chris McAuliffe, CEO and President of Theragen. "With thousands of patients already served by our professional and dedicated sales team, we were in a great position to add a key member to our leadership team to address the growing needs of our business."

ActaStim® is the first significant advancement in spinal fusion bone growth stimulator technology in nearly 20 years. It is the only system that combines clinically proven therapy, continuous wearability and actionable, daily patient insights to better support successful healing via its smartphone app, ActaStim Sync.

With more than 25 years of experience in the orthopedic and spine industry, Jim has a long history of high-growth performance for healthcare start-ups, mid-level companies and industry powerhouses including Medtronic, Orthologic (now Enovis), Spinal Elements, and most recently Zavation/Corelink.

Jim began his medical device career selling bone growth stimulators and has a 10-year track record of managing peak performance in that sector.

“It feels serendipitous to join a leadership team that is so dedicated to providing the most significant advancement of electrical stimulation technology in nearly 20 years,” Jim said. “I also have tremendous confidence in the leadership team and financial partners Ballast Point Ventures and RC Capital, who are helping to fuel the rapid growth at Theragen.”

About Theragen:

Theragen, Inc. is a leader in the development and manufacture of non-invasive, electrical stimulation DME products that deliver therapeutic energy to improve fusion success and empower patients to play an active role in their recovery. The company is committed to continuous innovation and expanding our reach to help improve outcomes for more patients. To learn more, please visit theragen.com.

About ActaStim® Bone Growth Stimulator System:

ActaStim uses safe, effective, FDA-approved stimulation technology that’s been prescribed clinically for over 20 years to improve spinal fusion success and help patients get back to the activities they enjoy.¹

SOURCE: Theragen

Media Contact:

Dawn Fallon
New Dawn Communications
dfallon@newdawncomms.com
Phone: 732-771-7808

¹U.S. Food and Drug Administration. (2020). PMA P190030: FDA Summary of Safety and Effectiveness Data.